Analysts Set Bausch + Lomb Co. (NYSE:BLCO) Price Target at $18.82

Shares of Bausch + Lomb Co. (NYSE:BLCO) have received an average rating of “Hold” from the twelve brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $18.82.

Several equities analysts have recently weighed in on BLCO shares. Bank of America cut their price objective on Bausch + Lomb from $18.00 to $17.00 and set an “underperform” rating on the stock in a report on Thursday, February 20th. HC Wainwright reissued a “buy” rating and set a $23.00 price target on shares of Bausch + Lomb in a research report on Tuesday, February 18th. Needham & Company LLC restated a “hold” rating on shares of Bausch + Lomb in a research note on Thursday, February 20th. Royal Bank of Canada decreased their price objective on Bausch + Lomb from $18.00 to $17.00 and set an “outperform” rating on the stock in a report on Friday, April 4th. Finally, Stifel Nicolaus decreased their target price on shares of Bausch + Lomb from $17.00 to $15.00 and set a “hold” rating on the stock in a research report on Thursday, April 3rd.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. boosted its stake in shares of Bausch + Lomb by 80.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 29,755 shares of the company’s stock valued at $576,000 after purchasing an additional 13,302 shares during the last quarter. HighTower Advisors LLC boosted its holdings in Bausch + Lomb by 14.7% during the 3rd quarter. HighTower Advisors LLC now owns 24,661 shares of the company’s stock worth $476,000 after acquiring an additional 3,164 shares during the last quarter. State Street Corp grew its holdings in shares of Bausch + Lomb by 5.6% in the third quarter. State Street Corp now owns 28,450 shares of the company’s stock valued at $549,000 after acquiring an additional 1,510 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Bausch + Lomb during the 3rd quarter worth $309,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Bausch + Lomb during the 3rd quarter worth approximately $555,000. Institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Price Performance

Shares of BLCO stock opened at $12.07 on Tuesday. The stock has a 50-day moving average price of $14.61 and a 200 day moving average price of $17.36. The company has a quick ratio of 1.01, a current ratio of 1.60 and a debt-to-equity ratio of 0.72. Bausch + Lomb has a 12 month low of $10.46 and a 12 month high of $21.69. The firm has a market cap of $4.26 billion, a price-to-earnings ratio of -13.26, a PEG ratio of 0.85 and a beta of 0.54.

Bausch + Lomb (NYSE:BLCO) last posted its earnings results on Wednesday, February 19th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.02. Bausch + Lomb had a positive return on equity of 3.35% and a negative net margin of 6.62%. The company had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.26 billion. During the same period in the previous year, the company earned $0.24 EPS. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. Research analysts expect that Bausch + Lomb will post 0.74 EPS for the current year.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.